The synergistic potential of combining PD-1/PD-L1 inhibitors with conventional therapies in esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC) is associated with a poor prognosis, and the efficacy of conventional therapies (chemotherapy, radiotherapy, and surgery) remains limited. The advent of programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has substantially altered the treatment paradigm for E...